Genetic testing company 23andMe announced that it would be slashing its workforce by 40%, which would mean rendering 200 employees jobless, as part of its restructuring initiative to cut costs.
In a press release on Monday, the leading human genetics and preventive health company, said the restructuring would allow the firm to cut operating costs and save more than $35 million a year.
